BullFrog to Host Webinar on New Precision AI Capability
March 27 webinar at 11 a.m. ET highlights launch of BullFrog AI’s new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design
GAITHERSBURG, Md., March 11, 2026 -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, will host a webinar in partnership with Xtalks Life Sciences, "Turning AI Recommendations into Clear, Defensible Decisions", about BullFrog AI’s new precision AI capability on Friday, March 27, 2026 at 11 a.m. ET.
The new AI capability advances the Company's end-to-end intelligence workflow by adding a strategic decision support layer on top of existing platforms bfPREP™ and bfLEAP®. Unlike traditional portfolio tools that collapse complex judgments into single scores and fixed weightings, the upcoming offering evaluates options using proprietary algorithms and methodologies, revealing which drug target discovery or clinical trial strategies are robust winners and which succeed only under narrow conditions.
Key capabilities of the new BullFrog AI platform include comparing drug programs, indications, and trial designs without forcing arbitrary numerical scores, as well as testing portfolio decisions against multiple specific scenarios and more. Please visit the BullFrog AI website for updates on the new product launch.
Webinar Speaker
The webinar will be led by Juan Felipe Beltrán Lacouture, PhD, BullFrog AI Senior Director of AI, Machine Learning & Innovation.
Webinar Overview
Hosted in partnership with Xtalks Life Sciences, the webinar will present BullFrog AI’s latest product, a novel structured decision-support tool that replaces arbitrary scoring with transparent, repeatable comparisons. The tool organizes available evidence, supports consistent evaluation across alternatives and generates outputs with a clear and auditable rationale. Rather than compressing uncertainty into a single composite score, the tool explicitly describes underlying assumptions and evidence drivers, enabling stakeholders to understand what influences a ranking and what conditions could alter an outcome.
Attendees will learn how structured decision environments can support cross-functional alignment, improve confidence in portfolio and trial strategy decisions and strengthen governance without requiring extensive system changes. Practical use cases will be discussed, including portfolio prioritization, target selection, biomarker strategy and clinical trial optimization.
Registration for this webinar can be found here.
About BullFrog AI
BullFrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP® platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information visit BullFrog AI at: https://bullfrogai.com.
About Xtalks Life Sciences
Xtalks Life Sciences brings together professionals across pharma, biotech, medtech, healthcare and research through trusted knowledge, meaningful connections and collaborative innovation. Focused on the highly regulated life sciences sector, the company delivers a dynamic portfolio of expert content, including webinars, news, blogs, podcasts, videos, virtual events and thought-provoking editorial offerings. These resources are designed to support informed decision-making and accelerate progress.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan Brings JPM Coin to Ethereum for Institutions
How Ethereum Could Stay Secure Even If Today’s Online Locks Stop Working
Cardano Price Prediction: Can ADA Defend $0.22 as Hoskinson Builds a New Programming Language?
VIPAI Asset Sell-Off and Selective Rotation in Crypto
1. Technology stocks fell sharply as investor interest shifted toward energy and selected defensive assets. From October 10 to 16, the Nasdaq 100 declined 5.49% and the S&P 500 fell 1.95%, while the Dow gained 0.67% and WTI crude rose 10.41%. BTC, ETH, and SOL declined 1.27%, 2.65%, and 4.44%, respectively. This week's technology earnings will be an important test of whether revenue growth, margins, and cash flow can justify current valuations. Better-than-expected results could help stabilize markets in the near term. 2. Crypto continues to see pockets of strong activity, but a broad-based altcoin season has yet to materialize. CoinMarketCap's (CMC) Altcoin Season Index stood at 54 as of the October 18 UTC daily observation, below the altcoin-season threshold of 75, while BTC dominance rose to 60.08%. Our proxy leverage ratio fluctuated between 4.00 and 4.07 during the week, showing no sustained increase and suggesting limited appetite for additional leverage. Meanwhile, as major exchanges expand access to traditional financial assets, the recent sell-off in AI-related equities could attract short-term speculative capital away from crypto. Such capital rotation could make it more difficult for a new altcoin season to take hold. 3. Papertrade's loss-to-mine model has generated significant interest across the crypto community. The protocol combines high-leverage derivatives trading with zero slippage and a mechanism that rewards trading losses with PAPER tokens. Across the eight complete UTC days from October 10 to 17, cumulative reported revenue reached approximately $56.08 million, including $51.90 million distributed to token holders. With growing participation from key opinion leaders (KOLs), Papertrade has reportedly ranked among the top three platforms by profitability in the broader market recently. Assets to watch: BTC, ETH, SOL, ARB, OP, SKHYNIX, SKHY, META, TSLA, LRCX, and SPCX. Key research priorities this week: Cash flow performance in technology earnings; the relative discount and holding costs of the two SK Hynix contracts; and U.S. initial jobless claims and PMI data. Weekly market data cover the period through October 16, while research information was verified through October 18. Observation periods are specified separately for each chart.
Crypto prices
More
